With step-by-step methods of drug production and knowledge of major unit operations and key concepts of pharmaceutical engineering, this guide will help to improve communication among the varied professionals working in the pharmaceutical industry. The updated volume reflects the acceleration occurring in processes to support new product development as the revolution initiated by characterization of the human genome at the turn of the millennium has an impact in transforming the treatment of disease.
Key Features
- The thoroughly revised and expanded professional text illustrates how materials that are being processed have evolved as the understanding of the cell biology and biochemistry of disease has improved and new treatments have emerged based on the products of biotechnology.
- Emphasizes the importance of pharmaceutical engineering and addresses the advances in disease therapy including their implications for pharmaceutical process engineering.
- Each topic has been updated to reflect new developments occurring in the last decade.
- Describes biosynthesis, of particular relevance to proteins and nucleic acids as well as gene transfer by transfection and editing used currently in cell therapies for a variety of rare diseases.
- Exciting new chapter on artificial intelligence and machine learning as tools for process optimization.
Anthony J. Hickey is Distinguished Fellow Emeritus at RTI International, Research Triangle Park, NC; Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy; and Adjunct Professor of Biomedical Engineering in the School of Medicine at the University of North Carolina at Chapel Hill. He is a Fellow of the American Association for the Advancement of Science, the American Association of Pharmaceutical Scientists, the Academy of Pharmaceutical Sciences of Great Britain, the Royal Society of Biology, the Royal Society of Medicine, and the National Academy of Inventors. He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan, the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists, Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine, and the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation. He is founder (and formerly President and CEO) of Cirrus Pharmaceuticals, Inc.; founder (formerly CSO) of Oriel Therapeutics, Inc,; CEO of Astartein, LLC.; Member of the Board of First Flight Venture Center, Inspiring Pty Ltd., and KAER Biotherapeutics; Chair of the USP Joint Sub-Committee on Nanotechnology; and Member of the USP Pharmaceutical Dosage Forms Expert Committee (DFEC) and Inhalation Sub-Committee of the DFEC of the United States Pharmacopeia. He consults on multidisciplinary research programs in the field of pulmonary drug and vaccine delivery for the treatment and prevention of a variety of diseases and serves on numerous editorial and scientific advisory boards.
